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AbstrAct
Objective There are currently five widely used definition 
of prediabetes. We compared the ability of these to predict 
5- year conversion to diabetes and investigated whether 
there were other cut- points identifying risk of progression 
to diabetes that may be more useful.
Research design and methods We conducted an 
individual participant meta- analysis using longitudinal 
data included in the Obesity, Diabetes and Cardiovascular 
Disease Collaboration. Cox regression models were used to 
obtain study- specific HRs for incident diabetes associated 
with each prediabetes definition. Harrell’s C- statistics were 
used to estimate how well each prediabetes definition 
discriminated 5- year risk of diabetes. Spline and receiver 
operating characteristic curve (ROC) analyses were used to 
identify alternative cut- points.
Results Sixteen studies, with 76 513 participants and 
8208 incident diabetes cases, were available. Compared 
with normoglycemia, current prediabetes definitions were 
associated with four to eight times higher diabetes risk (HRs 
(95% CIs): 3.78 (3.11 to 4.60) to 8.36 (4.88 to 14.33)) and 
all definitions discriminated 5- year diabetes risk with good 
accuracy (C- statistics 0.79–0.81). Cut- points identified 
through spline analysis were fasting plasma glucose (FPG) 
5.1 mmol/L and glycated hemoglobin (HbA1c) 5.0% (31 
mmol/mol) and cut- points identified through ROC analysis 
were FPG 5.6 mmol/L, 2- hour postload glucose 7.0 mmol/L 
and HbA1c 5.6% (38 mmol/mol).
Conclusions In terms of identifying individuals at 
greatest risk of developing diabetes within 5 years, using 
prediabetes definitions that have lower values produced 
non- significant gain. Therefore, deciding which definition 
to use will ultimately depend on the goal for identifying 
individuals at risk of diabetes.
significance of this study
What is already known about this subject?
 ► Prediabetes comprises heterogeneous states of im-
paired fasting glucose, impaired glucose tolerance 
or elevated glycated hemoglobin (HbA1c), which may 
have different underlying pathophysiologies.
 ► The definition of prediabetes has changed over time 
and there is no consensus as to the optimal definition 
for prediabetes in terms of identifying individuals at 
greatest risk of progressing to overt diabetes.
What are the new findings?
 ► All five current prediabetes definitions identified 
individuals at risk of developing diabetes within 
5 years with similar accuracy.
 ► Cut- points identified in this study were lower than 
the lower thresholds of the current definitions of 
prediabetes.
 ► Using diabetes definitions that have lower values to 
identify individuals at greatest risk of developing diabe-
tes within 5 years did not significantly improve prediction.
How might these results change the focus of 
research or clinical practice?
 ► Deciding which definition to use in research or clin-
ical practice will depend on the goal for identifying 
individuals at risk of diabetes.
 ► Two- hour postload plasma glucose (2hPG) and HbA1c 
data on the same participants are required to directly 
compare the strength of association and discrimina-
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InTROduCTIOn
Type 2 diabetes mellitus is one of the most important 
causes of morbidity and mortality globally. There are an 
estimated 425 million individuals aged 20–79 years world-
wide with diabetes, 90% of whom have type 2 diabetes 
and 212 million of them are living with undiagnosed 
diabetes.1 As type 2 diabetes is largely lifestyle- related 
and it is possible to delay or prevent onset through 
appropriate behavior modification, early identification 
of individuals most at risk of developing type 2 diabetes 
has become a cornerstone of public health and diabetes 
prevention policies.2 3
Although the relationship between blood glucose and 
vascular risk has been shown to be positive and increase 
monotonically from a low threshold,4 5 cut- points for 
fasting plasma glucose (FPG), 2- hour postload plasma 
glucose (2hPG) following an oral glucose challenge 
and glycated hemoglobin (HbA1c) are frequently used 
to diagnose diabetes and initiate treatment. Individuals 
with levels of glycemia that fall just below the cut- point 
for diabetes are considered to have ‘prediabetes’, a term 
that is often used to help identify individuals at risk of 
converting to overt diabetes, and who therefore may be 
most receptive to lifestyle interventions that prevent or 
delay onset. Prediabetes comprises heterogeneous states 
of impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT) or elevated HbA1c.6 Although each of 
these conditions may have different underlying patho-
physiologies, they have been reported to have similar 
diabetes progression rates in the range of 35.5–45.5 per 
1000 person- years for current definitions of prediabetes 
based on these measures.7 8
The definition of prediabetes has changed over time 
and there is currently no consensus as to the optimal 
definition for prediabetes in terms of identifying indi-
viduals at greatest risk of progressing to overt diabetes.9 
Based on the WHO IGT definition, there are an esti-
mated 352 million adults aged 20–79 years worldwide 
who are considered to have prediabetes,1 a figure that 
would increase if IFG was also included and increase 
substantially if a lower FPG threshold was to be adopted, 
as is advocated by the American Diabetes Association 
(ADA).10 Despite the current lack of evidence regarding 
how best to define prediabetes and little reliable infor-
mation regarding the risk of progression from predia-
betes to diabetes,11 both the UK and the USA have issued 
guidelines recommending screening for prediabetes.12 13 
There is a need for substantial evidence that could repre-
sent multiple geographical areas/populations in order to 
document the optimal diagnostic criteria.
The aims of the current study are twofold. First, to 
determine which of the current definitions of predia-
betes, advocated by ADA, WHO and the International 
Expert Committee (IEC), has the highest discrimina-
tory capacity for identifying individuals who convert to 
diabetes within 5 years from those who remain diabetes 
free, and to see how their performance varies by age, sex 
and geographical location. Second, to explore if there 
are other cut- points that are more useful in identifying 
risk of progression to diabetes.
ReseaRCH desIgn and meTHOds
The Obesity, Diabetes and Cardiovascular Disease Collab-
oration (ODCDC) is an international data pooling 
collaboration established to address outstanding issues 
of epidemiological and clinical importance involving 
indices of body size, markers of glucose homeostasis and 
risk of diabetes in diverse populations.14 The collabo-
ration encompasses populations from Asia, Australia, 
Europe, and North America. The original ODCDC data-
base was developed from a cleaned and coded dataset 
provided by investigators of the Collaborative Study of 
Obesity and Diabetes in Adults (CODA) after obtaining 
permission for data use from investigators of each of 
the prospective studies included in CODA. In 2016, we 
contacted investigators of existing and newly identified 
studies to provide data for all available study visits to 
develop a more comprehensive and informative dataset 
for the Collaboration.
In this study, participants with self- reported diabetes 
or newly diagnosed diabetes at baseline (n=8803) or 
who lacked information on diabetes status at baseline 
(n=1891) or follow- up (n=21 165) were excluded from 
analyses. Participants with missing data on age, body 
mass index (BMI), systolic blood pressure (SBP) and/or 
smoking status at baseline were also excluded (n=479).
definitions of prediabetes and incident diabetes
Based on the current cut- points recommended by 
WHO,15 16 ADA13 and IEC,17 we included two FPG- 
based, one 2hPG- based and two HbA1c- based defi-
nitions of prediabetes (table 1). The same cut- points 
were applied to studies that measured plasma glucose 
or serum glucose. Prediabetes was defined as FPG 
6.1–6.9 mmol/L according to the WHO- FPG cut- points, 
FPG 5.6–6.9 mmol/L according to the ADA- FPG cut- 
points, 2hPG 7.8–11.0 mmol/L according to both 
WHO and ADA, HbA1c 5.7%–6.4% (39–47 mmol/mol) 
according to the ADA- HbA1c cut- points and HbA1c 
6.0%–6.4% (42–47 mmol/mol) according to the IEC- 
HbA1c cut- points. To standardize diabetes definitions 
across studies and to take into account that the defi-
nitions may have changed during the study, incident 
diabetes identified in this study was based on blood 
tests, self- report and/or use of antidiabetic medications. 
Diabetes cases confirmed solely through sources such as 
registry data, medical records, etc were not considered 
here. For FPG- related analyses, we used incident diabetes 
as defined by self- report, use of antidiabetic medications 
and/or FPG≥7.0 mmol/L at follow- up. For 2hPG- related 
analyses, incident diabetes was classified by self- report, 
use of antidiabetic medications, FPG≥7.0 mmol/L 
and/or 2hPG≥11.1 mmol/L. For HbA1c- related anal-



















are: first published as 10.1136/bm






3BMJ Open Diab Res Care 2019;7:e000794. doi:10.1136/bmjdrc-2019-000794
Epidemiology/Health Services Research
Table 1 Definitions of glucose tolerance status used in this study
Definitions13 
15–17 Normal Prediabetes Incident diabetes
WHO- FPG FPG<6.1 mmol/L (110 mg/dL) FPG 6.1–6.9 mmol/L (110–
124 mg/dL)
Self- report, use of antidiabetic 
medications and/or FPG≥7.0 mmol/L 
(126 mg/dL) at follow- up.ADA- FPG FPG<5.6 mmol/L (101 mg/dL) FPG 5.6–6.9 mmol/L (101–
124 mg/dL)
2hPG 2hPG<7.8 mmol/L (141 mg/dL) 2hPG 7.8–11.0 mmol/L (141–
198 mg/dL)
Self- report, use of antidiabetic 
medications, FPG≥7.0 mmol/L (126 mg/dL) 
and/or 2hPG≥11.1 mmol/L (200 mg/dL) at 
follow- up.
ADA- HbA1c HbA1c<5.7% (39 mmol/mol) HbA1c 5.7%–6.4% (39–47 mmol/
mol)
Self- report, use of antidiabetic 
medications and/or HbA1c≥6.5% (48 
mmol/mol) at follow- up.IEC- HbA1c HbA1c<6.0% (42 mmol/mol) HbA1c 6.0%–6.4% (42–47 mmol/
mol)
ADA, American Diabetes Association; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; 2hPG, 2- hour postload plasma glucose; 
IEC, International Expert Committee.
of antidiabetic medications and/or HbA1c≥6.5% (48 
mmol/mol).
Time to diabetes was calculated as the time between 
baseline visit and diagnosis of diabetes based on blood 
testing during a follow- up visit. For participants who self- 
reported having diabetes or were on antidiabetic medica-
tions at follow- up, time to diabetes was estimated as the 
half- way point between the visit before diabetes was self- 
reported and the visit when diabetes was reported. Where 
age at diagnosis of diabetes was available, time to diabetes 
was calculated as the difference between age at baseline 
and age at diagnosis of diabetes. Participants who were 
lost to follow- up or free from diabetes by the end of the 
study period were censored. Each individual’s follow- up 
was censored at the time of death or last contact with the 
respective cohort study.
statistical analysis
Progression rates from prediabetes to diabetes were esti-
mated for each prediabetes definitions. Diabetes progres-
sion rate per 1000 person- years was calculated as the 
number of participants with prediabetes at baseline who 
were diagnosed with diabetes during follow- up divided by 
the total follow- up years of all participants with predia-
betes at baseline, and multiplied by 1000. Cox propor-
tional hazard regression models were used to obtain 
study- specific HRs and 95% CIs for incident diabetes that 
were associated with each of the five definitions. Normo-
glycemia or the state of non- prediabetes and diabetes 
(table 1), that is below each distinct index threshold of 
the respective measure, was the reference. Models were 
adjusted for age and sex and for age, sex, BMI, SBP, 
cigarette smoking and, where available, family history 
of diabetes. Random effects meta- analyses were used to 
pool study- specific log HRs to obtain overall estimate 
for each prediabetes definition. I2 statistics were used to 
quantify heterogeneity. The analyses were repeated by 
sex, age group, BMI- defined obesity status and country/
geographical region, and tests for heterogeneity across 
subgroups were obtained by meta- regression. Sensitivity 
analysis was conducted by excluding family history of 
diabetes in the multiple adjusted model. Analyses were 
repeated including only those studies that had measured 
both FPG and 2hPG or FPG and HbA1c at baseline to 
allow direct comparison of estimates between FPG and 
2hPG and between FPG and HbA1c. For these analyses, 
the definition of diabetes was modified to self- report, use 
of antidiabetic medication, FPG≥7.0 mmol/L and/or 
2hPG≥11.1 mmol/L in the FPG/2hPG analyses; and self- 
report, use of antidiabetic medication, FPG≥7.0 mmol/L 
and/or HbA1c≥6.5% in the FPG/HbA1c analyses.
Harrell’s C- statistics, stratified by study and adjusted 
for the above- mentioned covariates, were used to esti-
mate how well each prediabetes definition discriminated 
between those who developed diabetes over 5 years and 
those who did not. Participants who did not develop 
diabetes in the first 5 years from baseline were censored. 
Random effects meta- analyses were used to obtain pooled 
C- statistics for each prediabetes definition. These anal-
yses were repeated by subgroups mentioned above and 
tested for heterogeneity using meta- regression. In addi-
tion, the analyses were repeated on studies that measured 
both FPG and 2hPG or FPG and HbA1c at baseline and 
the modified definitions of diabetes as stated above were 
used.
Restricted cubic splines with four knots were used to 
examine the relationship between each of the three base-
line measures of glycemia and incident diabetes. Knots 
were defined based on Harrell’s recommended percen-
tiles.18 Reference was chosen as the mean rounded to 
the nearest whole number. A series of single knot linear 
splines were fitted to explore if threshold associations 
exist between each of the three baseline measures of 
glycemia and incident diabetes. The optimal cut- point 
was taken to be the knot that corresponded to the 
smallest Akaike information criterion value. Spline anal-
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Table 2 Pooled HRs for incident diabetes association with prediabetes status at baseline and Harrell’s C- statistics for 
predicting 5- year risk of diabetes associated with prediabetes status at baseline
Prediabetes definition
Multiple adjusted*
N HR (95% CI)† I2 (%) C- statistics (95% CI)† I2 (%)
WHO- FPG‡ 73 151 5.54 (4.31 to 7.12) 93.9 0.789 (0.772 to 0.807) 63.5
ADA- FPG‡ 73 151 4.17 (3.36 to 5.17) 93.3 0.803 (0.787 to 0.819) 62.2
2hPG 12 846 3.78 (3.11 to 4.60) 66.4 0.793 (0.774 to 0.812) 0
ADA- HbA1c 19 375 7.81 (4.32 to 14.14) 94.9 0.811 (0.724 to 0.899) 97.9
IEC- HbA1c 19 375 8.36 (4.88 to 14.33) 93.9 0.802 (0.729 to 0.874) 96.2
*Age, sex, body mass index, systolic blood pressure, smoking and family history of diabetes.
†Normal (non- prediabetes or diabetes) was the reference group, see table 1 for the respective definitions.
‡Family history of diabetes was not adjusted for MESA and Aichi.
ADA, American Diabetes Association; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; 2hPG, 2- hour postload plasma glucose; 
IEC, International Expert Committee.
with adjustments for age, sex, study, BMI, SBP, cigarette 
smoking and family history of diabetes. In addition, 
receiver operating characteristic curve (ROC) analyses 
were conducted to determine optimal cut- points for 
discriminating 5- year diabetes risk. The optimal cut- point 
was taken to be the value where the sum of sensitivity and 
specificity is at maximum and that sensitivity and speci-
ficity are both >50% to protect against unacceptable rates 
of classification error.
Population attributable fraction of diabetes was calcu-
lated for each prediabetes definition using the formula: 
100×prevalence×(HR–1)/[100+prevalence×(HR–1)]. 
Age- and sex- adjusted HRs were used in these calculations.
All statistical analyses were performed using Stata/SE 
V.14.0 (StataCorp, College Station, Texas, USA).
ResulTs
Sixteen studies contributed information on 76 513 partic-
ipants in whom 8208 cases of FPG- defined incident 
diabetes developed over a mean follow- up of 11.1 years 
(range 4.9–21.7 years). Of these studies, five were from 
Australia, four from the USA, two each from Japan and 
Sweden and one each from Iran, Mexico and Spain. 
While all studies collected FPG (mean 5.2 mmol/L; 
range of mean values 4.1–5.5 mmol/L), four studies 
additionally collected 2hPG (mean 6.0 mmol/L; range 
5.5–6.1 mmol/L) and five studies collected HbA1c (mean 
5.3% (34 mmol/mol); range 5.1%–5.5% (32–37 mmol/
mol)). Baseline characteristics of participants by study 
are shown in online supplementary sTable 1. In brief, 
mean (SD) age at baseline was 49.6 (12.7) years, mean 
BMI was 26.3 (5.0) kg/m2, mean SBP was 125.0 (19.1) 
mm Hg, 51.7% of participants were female, 19.1% were 
current smokers and 20.8% had a family history of 
diabetes. Progression from prediabetes to diabetes was 
45.7 per 1000 person- years (range 20.0–138.4 per 1000 
person- years) for WHO- FPG- defined prediabetes, 23.7 
per 1000 person- years (range 11.2–80.8 per 1000 person- 
years) for ADA- FPG- defined prediabetes, 43.8 per 1000 
person- years (range 30.5–62.2 per 1000 person- years) for 
2hPG, 45.2 per 1000 person- years (range 31.0–87.7 per 
1000 person- years) for ADA- HbA1c and 79.4 per 1000 
person- years (range 51.1–154.3 per 1000 person- years) 
for IEC- HbA1c (online supplementary sTable 2).
association between prediabetes and risk of diabetes
From 74 095 participants with measured FPG and no 
diabetes at baseline, 8208 cases of incident diabetes as 
defined by self- report, use of antidiabetic medications 
and/or FPG≥7.0 mmol/L, over 825 051 person- years 
of follow- up were included in analyses involving FPG. 
Compared with the normal FPG group, WHO- FPG- 
defined prediabetes at study baseline was associated with 
an age- and sex- adjusted HR (95% CIs) of 7.50 (5.86 
to 9.60) (online supplementary sFigure 1), which was 
attenuated with further adjustment (multiple adjusted 
HR 5.54 (4.31 to 7.12); table 2). When the ADA- FPG 
cut- points were used, the association between predia-
betes and diabetes relative to normal FPG was also strong 
(multiple adjusted HR 4.17 (3.36 to 5.17); table 2; online 
supplementary sFigure 2). Heterogeneity was observed 
between studies for all analyses (I2 range 93.3%–94.2%). 
The results were not significantly different between men 
and women (p=0.511–0.553), between younger and 
older age groups (0.873–0.926), nor between countries/
geographical regions irrespective of which fasting cut- 
point was used (0.128–0.133; figure 1; online supplemen-
tary sTable 3). The results for WHO- FPG were, however, 
different between BMI- defined obesity subgroups with 
stronger associations observed in the normal weight 
group (multiple adjusted HR: BMI 18.5–24.9 kg/m2 
10.49 (7.20 to 15.27); BMI 25.0–29.9 kg/m2 6.56 (4.86 to 
8.86); BMI≥30 kg/m2 4.36 (3.36 to 5.68); p<0.001; online 
supplementary sTable 4). Excluding family history of 
diabetes from the multiple adjusted model did not mate-
rially alter the relationships.
In four studies including 13 536 participants without 
diabetes (145 206 person- years of follow- up) who had 
2hPG measured at baseline, 1787 cases of incident diabetes 
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Figure 1 Associations between prediabetes and 
diabetes by prediabetes definition and (A) sex, (B) age 
group. HRs adjusted for age, body mass index, systolic 
blood pressure, smoking and family history of diabetes; 
normal (ie, non- prediabetes or diabetes) was the reference 
group. ADA, American Diabetes Association; FPG, fasting 
plasma glucose; HbA1c, glycated hemoglobin; 2hPG, 2- 
hour postload plasma glucose; IEC, International Expert 
Committee. See table 1 for the respective definitions.
FPG≥7.0 mmol/L and/or 2hPG≥11.1 mmol/L were 
identified. Participants with 2hPG- defined prediabetes 
had almost four times the risk of diabetes as those with 
normal 2hPG (multiple adjusted HR: 3.78 (3.11 to 4.60); 
I2=66.4%; table 2; online supplementary sFigure 3). As 
for FPG- defined prediabetes, there was no evidence of 
a sex- difference (p=0.702), an age- difference (p=0.929), 
nor a body size- difference (p=0.052) in the 2hPG asso-
ciation (figure 1; online supplementary sTable 4). One 
study contributed data to each country/region; there was 
no observable difference in the associations between the 
four countries (multiple adjusted HRs range from 3.04 
(2.17 to 4.26) for Spain to 4.82 (3.93 to 5.91) for Australia; 
p=0.303; online supplementary sTable 3). Excluding 
family history of diabetes in the multiple adjusted model 
did not materially alter the relationships.
For analyses concerning HbA1c, five studies with 19 975 
participants free of diabetes who had HbA1c measured 
at baseline, 1560 cases of incident diabetes as defined 
by self- report, use of antidiabetic medications and/or 
HbA1c≥6.5%, and 145 682 person- years of follow- up were 
included. Participants with ADA- HbA1c- defined predia-
betes had approximately eight times the risk of a subse-
quent diagnosis of diabetes than those with HbA1c<5.7% 
(multiple adjusted HR: 7.81 (4.32 to 14.14); I2=94.9%; 
table 2; online supplementary sFigure 4s). Similarly, 
those with IEC- HbA1c- defined prediabetes had roughly 
eight times higher risk of developing diabetes than those 
with normal HbA1c but again with considerable between- 
study heterogeneity (8.36 (4.88 to 14.33); I2=93.9%; 
table 2; online supplementary sFigure 5). The results 
were similar between men and women (p=0.921–0.930), 
between- age groups (0.342–0.655), between countries 
(0.505–0.555) and between obesity status (0.123–0.145; 
figure 1; online supplementary sTables 3–4). The results 
were unaffected by excluding family history of diabetes 
from the multiple adjusted model.
When the analyses were repeated restricted to studies 
that had measured both FPG and 2hPG at baseline 
(n=12 844), the relationship between incident diabetes 
(defined by self- report, use of antidiabetic medications, 
FPG≥7.0 mmol/L and/or 2hPG≥11.1 mmol/L) and 
2hPG- defined prediabetes had a higher HR than either 
of the FPG definitions of prediabetes, although CIs over-
lapped (online supplementary sTable 5). For the anal-
yses on studies that had measured both FPG and HbA1c 
at baseline (n=16 979), the relationship with incident 
diabetes (defined by self- report, use of antidiabetic medi-
cations, FPG≥7.0 mmol/L and/or HbA1c≥6.5%) was 
highest for IEC- HbA1c- defined prediabetes, although 
CIs also overlapped.
ability of prediabetes to discriminate between people who 
developed diabetes over 5 years or not
The discriminatory ability for 5- year risk of diabetes 
was similar between all five prediabetes definitions 
(online supplementary sFigures 6–10; table 2). The 
multiple adjusted C- statistics ranged from 0.789 (0.772 
to 0.807) for WHO- FPG- defined prediabetes to 0.811 
(0.724 to 0.899) for ADA- HbA1c- defined prediabetes 
(table 2). Apart from the 2hPG prediabetes definition, 
between- study heterogeneity was observed in all anal-
yses (I2=62.2%–97.9%). The discriminatory ability was 
not significantly different between men and women 
(p=0.137–0.938), between- age groups (0.290–0.731), nor 
between countries/geographical regions (0.401–0.949; 
online supplementary sTables 6–8). The discriminatory 
ability for WHO- FPG- defined prediabetes was, however, 
better in the BMI- defined normal weight group than in 
groups with higher BMI (multiple adjusted C- statistics: 
BMI 18.5–24.9 kg/m2 0.795 (0.759 to 0.831); BMI 25.0–
29.9 kg/m2 0.770 (0.728 to 0.812); BMI≥30 kg/m2 0.734 
(0.698 to 0.771); p=0.003; online supplementary sTable 
9).
When the analyses were restricted to those studies 
that had measured both FPG and 2hPG at baseline, 
the C- statistic was higher for the 2hPG- defined predia-
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WHO- FPG- defined prediabetes (0.738 (0.718 to 0.758); 
online supplementary sTable 5). For analyses that were 
restricted to studies that had measured both FPG and 
HbA1c, the C- statistics were not different between the 
prediabetes definitions.
shape of relationships between measures of glycemia and 
incident diabetes
The relationship between 2hPG and incident diabetes 
appeared log- linear from 2hPG 5.0 mmol/L to below the 
cut- point for diabetes (=11.0 mmol/L, online supplemen-
tary sFigure 11a). In contrast, a non- linear relationship 
was observed between FPG and incident diabetes with 
the angle of the slope increasing at approximately FPG 
4.5, 5.0 and 5.5 mmol/L (online supplementary sFigure 
11b). A non- linear relationship was similarly observed 
between HbA1c and incident diabetes with the change 
in slope occurring at approximately HbA1c 4.5% (26 
mmol/mol), 5.0% (31 mmol/mol) and 5.5% (37 mmol/
mol; online supplementary sFigure 11c).
Based on multiple adjusted single knot linear spline 
models, the mathematically optimal cut- points associated 
with incident diabetes were FPG 5.1 mmol/L and HbA1c 
5.0% (31 mmol/mol). A cut- point was not derived for 
2hPG due to the log- linear relationship observed. The 
multiple adjusted C- statistics for prediabetes based on 
these cut- points were 0.783 (0.762 to 0.804) (I2=79.9%) 
for FPG and 0.754 (0.692 to 0.817) (I2=94.7%) for HbA1c. 
The proportions of participants classified as having 
prediabetes at baseline according to these cut- points 
were 56.7% for FPG and 77.8% for HbA1c (table 3). 
Progression from prediabetes to diabetes based on these 
cut- points were 14.4 per 1000 person- years for FPG and 
13.7 per 1000 person- years for HbA1c.
According to the ROC analysis, the optimal cut- points 
for discriminating 5- year risk of diabetes were FPG 
5.6 mmol/L (sensitivity=64.1%, specificity=77.0%), 2hPG 
7.0 mmol/L (sensitivity=62.0%, specificity=80.9%) and 
HbA1c 5.6% (38 mmol/mol; sensitivity=72.8%, speci-
ficity=79.6%). Compared with these cut- points, current 
prediabetes definitions with higher cut- points (ie, WHO- 
FPG, 2hPG and IEC- HbA1c) have significantly lower 
sensitivity but higher specificity and positive predictive 
values. In contrast, cut- points derived from spline analysis 
have substantially higher sensitivity but lower specificity 
and positive predictive values (table 3).
The fraction of diabetes attributable to prediabetes 
ranged from 32.5% to 61.7% for FPG, 30.5% to 38.8% 
for 2hPG and 37.6% to 74.5% for HbA1c (table 3).
COnClusIOns
Prediabetes is a contentious term for levels of glycemia 
that are elevated above the normal range but below the 
level used to define diabetes, as many people classified 
with prediabetes do not progress to overt diabetes and 
may even revert to normoglycemia.11 19 Adding to the 
complexity is that, depending on region of the world, up 
to five different methods for defining prediabetes are in 
use. The results of our individual participant meta- analysis 
showed that all current prediabetes definitions were asso-
ciated with an increased risk of diagnosed diabetes and 
all of them identified people at high risk for a subsequent 
diabetes diagnosis within 5 years with reasonably good 
accuracy. All variables in the multiple- adjusted models 
were associated with diabetes risk and the association was 
strongest for family history of diabetes (HRs 1.53–1.64). 
Our findings were consistent across groups that differed 
on the basis of sex, age and geographical region. Further-
more, cut- points identified here were lower than those 
used in current prediabetes definitions.
Similar to our study, a recent systematic review reported 
the risk of developing diabetes varied by prediabetes defi-
nitions and found no clear pattern of difference between 
geographical regions.11 The review also showed that 
for people with prediabetes, the overall risk of diabetes 
increased over time while the likelihood of regression 
to normoglycemia decreased over time. Surprisingly 
though, regression to normoglycemia was observed even 
after 11 years of follow- up.
A US study reported small, but significant, differences 
in C- statistics for predicting diagnosed diabetes between 
the prediabetes definitions analyzed here, with higher 
values observed in FPG- based than HbA1c- based defini-
tions.20 In contrast, C- statistics in our study were higher 
for HbA1c- based than FPG- based definitions in the 
subgroup with both FPG and HbA1c data, although CIs 
overlapped. Similarly, higher C- statistics, with overlap-
ping CIs, were observed for the 2hPG definition when 
compared with FPG- based definitions. Nevertheless, the 
difference between the highest and lowest C- statistics 
was small, hence, impact on the overall discriminatory 
accuracy between the definitions in practice would be 
negligible.
In addition to comparing the relationship between 
current prediabetes definitions and incident diabetes, 
we identified mathematically optimal definitions of 
prediabetes for FPG and HbA1c. As reported in a Dutch 
study, non- linear relationships were observed for FPG 
and HbA1c and incident diabetes.21 Our results showed 
the slope was steeper from approximately 5.0 mmol/L 
for FPG and from approximately 5.0% (31 mmol/mol) 
for HbA1c. Similarly, an Israeli study found men with 
higher FPG within the normal range had progressively 
increased risk of diabetes compared with men with 
FPG<4.5 mmol/L.22 Furthermore, our results from single 
knot spline analysis suggested that the optimal cut- points 
for FPG or HbA1c associated with incident diabetes fell 
within the normoglycemic range while cut- points identi-
fied through ROC analysis were in line with the ADA defi-
nitions possibly because similar approach was used (ie, 
sensitivity and specificity had to be ≥50%). Other studies 
have also reported optimal cut- points that are below 
the lower limit of current prediabetes definitions.23 24 
Whether a lower cut- point is considered appropriate or 
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prediction or targeting intervention strategies and 
prevention). Lowering the current prediabetes cut- points 
to the level suggested here would identify substantially 
more participants with prediabetes at baseline but the 
rate of progression from prediabetes to diabetes would 
be lower. As there is limited evidence of benefit of inter-
vention in individuals with IFG,25 26 let alone normogly-
cemia, it seems inappropriate to recommend lowering of 
cut- points for prediabetes for the purpose of initiating 
treatment such as pharmacotherapy. Moreover, reclassi-
fying otherwise healthy individuals as having prediabetes 
may confer psychological distress or economic harm.27 28 
On the other hand, lowering the cut- points may offer 
more opportunity to prevent progression to diabetes 
through lifestyle interventions at a population level.
The strength of our study was the use of individual 
participant data from 16 studies. Nevertheless, a few 
limitations warrant mention. Between- study heteroge-
neity was generally high across all analyses; analysis by 
subgroups did not identify possible sources of heteroge-
neity. Variability of HbA1c assays used between studies 
and within studies over time may have partly contrib-
uted to the high heterogeneity in analyses related to 
HbA1c. Nevertheless, four of the five studies that 
measured HbA1c conducted baseline and last follow- up 
visits over similar periods. We were unable to directly 
compare the strength of association and discriminatory 
ability of 2hPG- based and HbA1c- based prediabetes 
definitions in the same participants as only one study 
had all three measures of glycemia. Furthermore, those 
who died before follow- up were more likely to have 
developed diabetes which would have been missed by 
our studies, given the increased risk of death associ-
ated with diabetes.20 29–32 If mortality differed between 
the prediabetes categories, this might lead to different 
degrees of underestimation of true incidence between 
the categories. The lack of studies that had collected 
2hPG and/or HbA1c also reduced the generalizability 
of the results by country/geographical region as most 
of the subgroups included only one study. Moreover, we 
were unable to examine how the relationship may vary 
by ethnic/race group. Furthermore, unlike mortality as 
an outcome which is accompanied by a date of death, 
time to diabetes is an approximation.
All current prediabetes definitions were associated 
with greater risk of diabetes relative to people with lower 
glucose concentrations and identified people at risk of 
developing diabetes within 5 years with similar accuracy. 
Therefore, deciding which definition to use will ulti-
mately depend on the allocation of healthcare resources 
available to intervene in individuals designated at high 
risk, and the need to balance sensitivity with specificity. 
Unsurprisingly, using a lower glycemic threshold to 
define prediabetes will increase the number of individ-
uals who may qualify for an intervention but at the risk 
of treating many individuals who are less likely to prog-
ress to diabetes. As suggested in the WHO/International 
Diabetes Federation 2006 report,15 including known 
diabetes risk factors in the assessment of risk rather than 
basing it on a single measure of glycemia would be a 
better and more nuanced approach to identifying those 
most at risk of developing diabetes and in need of subse-
quent intervention.
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